These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18647474)

  • 21. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS.
    Delahunty T; Bushman L; Fletcher CV
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jan; 830(1):6-12. PubMed ID: 16269276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).
    Parks DA; Jennings HC; Taylor C; Pakes GE; Acosta EP
    HIV Clin Trials; 2009; 10(3):160-7. PubMed ID: 19632955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantification of tenofovir in human plasma by solid-phase extraction and high-performance liquid chromatography coupled with UV detection.
    Kou H; Du X; Li Y; Fu Q; Zhu Z; Li T
    Ther Drug Monit; 2012 Oct; 34(5):593-8. PubMed ID: 22960734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic profiling of efavirenz-emtricitabine-tenofovir fixed dose combination in pregnant and non-pregnant rats.
    Nirogi R; Bhyrapuneni G; Kandikere V; Muddana N; Saralaya R; Komarneni P; Mudigonda K; Mukkanti K
    Biopharm Drug Dispos; 2012 Jul; 33(5):265-77. PubMed ID: 22610784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
    Anderson PL; Glidden DV; Liu A; Buchbinder S; Lama JR; Guanira JV; McMahan V; Bushman LR; Casapía M; Montoya-Herrera O; Veloso VG; Mayer KH; Chariyalertsak S; Schechter M; Bekker LG; Kallás EG; Grant RM;
    Sci Transl Med; 2012 Sep; 4(151):151ra125. PubMed ID: 22972843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
    Gallien S; Flandre P; Nguyen N; De Castro N; Molina JM; Delaugerre C
    J Med Virol; 2015 Feb; 87(2):187-91. PubMed ID: 25070158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course.
    Prada N; Davis B; Jean-Pierre P; La Roche M; Duh FM; Carrington M; Poles M; Mehandru S; Mohri H; Markowitz M
    J Acquir Immune Defic Syndr; 2008 Oct; 49(2):117-22. PubMed ID: 18769360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.
    D'Avolio A; Simiele M; Siccardi M; Baietto L; Sciandra M; Oddone V; Stefani FR; Agati S; Cusato J; Bonora S; Di Perri G
    J Pharm Biomed Anal; 2011 Mar; 54(4):779-88. PubMed ID: 21071165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
    Elion R; Cohen C; Ward D; Ruane P; Ortiz R; Reddy YS; Ebrahimi R; McColl D; Kearney B; Fisher A; Flaherty J;
    HIV Clin Trials; 2008; 9(4):213-24. PubMed ID: 18753116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of micellar liquid chromatography to analyze darunavir, ritonavir, emtricitabine, and tenofovir in plasma.
    Peris-Vicente J; Villarreal-Traver M; Casas-Breva I; Carda-Broch S; Esteve-Romero J
    J Sep Sci; 2014 Oct; 37(20):2825-32. PubMed ID: 25103282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection.
    Bushman LR; Kiser JJ; Rower JE; Klein B; Zheng JH; Ray ML; Anderson PL
    J Pharm Biomed Anal; 2011 Sep; 56(2):390-401. PubMed ID: 21715120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitive determination of tenofovir in human plasma samples using reversed-phase liquid chromatography.
    Sentenac S; Fernandez C; Thuillier A; Lechat P; Aymard G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Aug; 793(2):317-24. PubMed ID: 12906906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde.
    Sparidans RW; Crommentuyn KM; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jul; 791(1-2):227-33. PubMed ID: 12798182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A liquid chromatography tandem mass spectrometry based regulatory compliant method for the determination of tenofovir in human serum.
    Paliwal N; Jain P; Dubey N; Sharma S; Khurana S; Kumar Paliwal S
    Drug Res (Stuttg); 2014 Jun; 64(6):306-12. PubMed ID: 24310362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for simultaneous determination of tenofovir and emtricitabine in human plasma and its application to a bioequivalence study.
    Gomes NA; Vaidya VV; Pudage A; Joshi SS; Parekh SA
    J Pharm Biomed Anal; 2008 Nov; 48(3):918-26. PubMed ID: 18783908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.
    Uglietti A; Zanaboni D; Gnarini M; Maserati R
    Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1305-14. PubMed ID: 22943210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction.
    Rezk NL; Crutchley RD; Kashuba AD
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Aug; 822(1-2):201-8. PubMed ID: 16005269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and evaluation of molecularly imprinted polymeric microspheres for highly selective extraction of an anti-AIDS drug emtricitabine.
    Lai JP; Xie L; Sun H; Chen F
    Anal Bioanal Chem; 2013 May; 405(12):4269-75. PubMed ID: 23503744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.